AVEO Pharmaceuticals (AVEO) Plans Presentation of Final TIVO-1 Extension Study Results
Tweet Send to a Friend
AVEO Pharmaceuticals (NASDAQ: AVEO) announced that final results from the TIVO-1 extension study, known as Study 902, in which patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
